Medicine and Dentistry
Overall Survival
85%
Immune Checkpoint Inhibitor
69%
Non Small Cell Lung Cancer
69%
Neoplasm
38%
Immunotherapy
38%
Malignant Neoplasm
36%
Skeletal Muscle
34%
Lung Cancer
31%
Randomized Controlled Trial
27%
Prognostic Factor
24%
Cancer Staging
22%
Observational Study
22%
Proportional Hazards Model
22%
Liver Metastasis
21%
Cohort Analysis
19%
Protein Intake
19%
Gemcitabine
19%
Clinical Trial
19%
Diagnosis
17%
Glioblastoma
17%
Clinical Feature
17%
Personalized Medicine
17%
Oligoastrocytoma
17%
Cancer Therapy
17%
Patient-Reported Outcome
17%
Bladder Cancer
17%
Muscle Invasive Bladder Cancer
17%
Cystectomy
17%
Neoadjuvant Chemotherapy
17%
Clinical Stage
17%
Arm
17%
Gene Expression Profiling
17%
Lymphocyte
17%
Targeted Therapy
17%
Gene Expression
17%
Ganglioglioma
13%
Bone Metastasis
11%
Metastatic Urinary Tract Cancer
11%
Oncology
11%
Body Weight
10%
Outcome Assessment
10%
Cancer Registry
9%
Progression Free Survival
9%
Risk Stratification
8%
Carboplatin
8%
Immunohistochemistry
8%
Epidermal Growth Factor Receptor
8%
Cachexia
8%
Time to Treatment
6%
Survival Analysis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Immune Checkpoint Inhibitor
52%
Non Small Cell Lung Cancer
49%
Immunotherapy
44%
Malignant Neoplasm
38%
Gemcitabine
34%
Cisplatin
29%
Randomized Controlled Trial
27%
Chemotherapy
26%
Pembrolizumab
20%
Muscle Invasive Bladder Cancer
17%
Bladder Cancer
17%
Vinflunine
17%
Clinical Feature
17%
Progression Free Survival
16%
Liver Metastasis
16%
Clinical Trial
16%
Urinary Tract Cancer
14%
Bone Metastasis
11%
Cancer Registry
9%
Lung Cancer
9%
Carboplatin
8%
Side Effect
8%
Comorbidity
6%
Symptom
6%
Adverse Event
5%
Neoplasm
5%
Keyphrases
Substantial Clinical Benefit
17%
Late-stage Cancer
17%
Subsequent Line
17%
Pretreated Patients
17%
Survival Benefit
17%
Well-nourished
17%
Diffuse Astrocytoma
17%
IDH-wildtype
17%
Immune Checkpoint Inhibitors
17%
Advanced Urothelial Carcinoma
17%
Cisplatin-ineligible
17%
Vinflunine
17%
Tumor-associated
17%
Independent Prognostic Factor
17%
CD66b
17%
Real-world Treatment Patterns
17%
Overall Survival
14%
Molecular Tumor Board
13%
CD163+ Macrophages
11%
Preapproval
11%
Lung Cancer Registry
11%
Muscle Maintenance
8%
Muscle Wasting
8%
Time to Treatment Discontinuation
8%
Short-term Recurrence
8%
CD8+ T Lymphocytes
8%
Grain Products
6%
Animal Products
6%
Performance Status
5%
Treatment Information
5%
Post-approval Changes
5%
Non-small Cell Lung Cancer (NSCLC)
5%
Liver Metastasis
5%
